Should I buy BioLife Solutions, Inc. (BLFS) stock or is it too late?

BioLife Solutions, Inc. · Health Care · price $37

See the full BioLife Solutions, Inc. (BLFS) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Lake Street — 65% of its targets hit on this sector (26 calls tested). It aims for $31 (-17 %), call made on July 23, 2026, maturing on July 23, 2027 (36 d ago).

The 3 reliable analysts $31-17 %

The 2 other firms $31-17 %

How to read it: the 3 reliable firms are not filtered by optimism — 0 aim above the price, 3 below, hence their $31 median. “The 2 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on BioLife Solutions, Inc.

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
HC Wainwright & Co.	75 %	+68.0 %	8	$31 -17%
Keybanc	40 %	+2.5 %	5	$33 -11%

In short — Should you invest in BioLife Solutions, Inc.? Is it too late, still worth it? Analysts are split (0% buy, median target $31, i.e. -17%). But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Few solid positives from analysts right now: of 6 ratings, only 0 buys, and the median price target ($31) is -17% below the price ($37). Caution prevails.

⚠️ Reasons to hesitate

Even the most reliable firm on BLFS, Lake Street (100% hit rate, 2 scored calls), only targets $31 (call made on July 22, 2026, maturing on July 22, 2027) (-17%) in its most recent call. The stock may already have run past its target.
The consensus is not unanimous: of 6 ratings, 6 are neutral.
Limited upside: the median target is only -17% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on BLFS

Median target $31 (-17%) · 6 ratings · Hold consensus

Strong Buy00%

Buy00%

Hold6100%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in BioLife Solutions, Inc. now?

We won't decide for you. The facts: 0% of analysts rate it a buy, median target $31 (-17%), and Lake Street (most reliable on BLFS, 100%) targets $31. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in BioLife Solutions, Inc.?

The stated upside is small: the median target ($31) sits just -17% from the price ($37) (most reliable on BLFS: Lake Street, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is BioLife Solutions, Inc. still worth investing in?

It depends on the gap between the price ($37) and its estimated value: analysts target $31 on median (-17%), with 0% buys (most reliable on BLFS: Lake Street, 100%). Cross-check with their real reliability on BLFS and the cautions above. Information, not advice.

What's the main risk in buying BLFS?

Even the most reliable firm on BLFS, Lake Street (100% hit rate, 2 scored calls), only targets $31 (call made on July 22, 2026, maturing on July 22, 2027) (-17%) in its most recent call. The stock may already have run past its target.

→ Go deeper: the full BioLife Solutions, Inc. profile (consensus, analyst reliability, price target, performance).